Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
J Exp Med ; 203(1): 153-63, 2006 Jan 23.
Article in English | MEDLINE | ID: mdl-16401693

ABSTRACT

The cell surface receptor alpha4 integrin plays a critical role in the homing, engraftment, and maintenance of hematopoietic progenitor cells (HPCs) in the bone marrow (BM). Down-regulation or functional blockade of alpha4 integrin or its ligand vascular cell adhesion molecule-1 mobilizes long-term HPCs. We investigated the role of alpha4 integrin in the mobilization and homing of BM endothelial progenitor cells (EPCs). EPCs with endothelial colony-forming activity in the BM are exclusively alpha4 integrin-expressing cells. In vivo, a single dose of anti-alpha4 integrin antibody resulted in increased circulating EPC counts for 3 d. In hindlimb ischemia and myocardial infarction, systemically administered anti-alpha4 integrin antibody increased recruitment and incorporation of BM EPCs in newly formed vasculature and improved functional blood flow recovery and tissue preservation. Interestingly, BM EPCs that had been preblocked with anti-alpha4 integrin ex vivo or collected from alpha4 integrin-deficient mice incorporated as well as control cells into the neovasculature in ischemic sites, suggesting that alpha4 integrin may be dispensable or play a redundant role in EPC homing to ischemic tissue. These data indicate that functional disruption of alpha4 integrin may represent a potential angiogenic therapy for ischemic disease by increasing the available circulating supply of EPCs.


Subject(s)
Integrin alpha4/metabolism , Myocardial Ischemia/physiopathology , Neovascularization, Physiologic , Stem Cells/physiology , Animals , Bone Marrow , Cell Movement , Endothelial Cells , Integrin alpha4/genetics , Male , Mice , Mice, Knockout
2.
Nat Med ; 11(11): 1197-204, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16244652

ABSTRACT

Sonic hedgehog (Shh) is a crucial regulator of organ development during embryogenesis. We investigated whether intramyocardial gene transfer of naked DNA encoding human Shh (phShh) could promote a favorable effect on recovery from acute and chronic myocardial ischemia in adult animals, not only by promoting neovascularization, but by broader effects, consistent with the role of this morphogen in embryogenesis. After Shh gene transfer, the hedgehog pathway was upregulated in mammalian fibroblasts and cardiomyocytes. This resulted in preservation of left ventricular function in both acute and chronic myocardial ischemia by enhanced neovascularization, and reduced fibrosis and cardiac apoptosis. Shh gene transfer also enhanced the contribution of bone marrow-derived endothelial progenitor cells to myocardial neovascularization. These data suggest that Shh gene therapy may have considerable therapeutic potential in individuals with acute and chronic myocardial ischemia by triggering expression of multiple trophic factors and engendering tissue repair in the adult heart.


Subject(s)
Genetic Therapy , Heart/embryology , Myocardium/metabolism , Signal Transduction , Trans-Activators/therapeutic use , Acute Disease , Animals , COS Cells , Cells, Cultured , Chlorocebus aethiops , Chronic Disease , Disease Models, Animal , Echocardiography , Fibroblasts/metabolism , Gene Expression Regulation, Developmental , Hedgehog Proteins , Humans , Mice , Mice, Mutant Strains , Myocardial Ischemia/etiology , Myocardial Ischemia/metabolism , Myocardial Ischemia/physiopathology , Myocardial Ischemia/therapy , Myocardium/cytology , Myocytes, Cardiac/metabolism , Neovascularization, Physiologic , RNA, Messenger/metabolism , Rats , Reverse Transcriptase Polymerase Chain Reaction , Swine , Ventricular Function, Left/physiology
3.
Circulation ; 115(25): 3165-72, 2007 Jun 26.
Article in English | MEDLINE | ID: mdl-17562958

ABSTRACT

BACKGROUND: A growing population of patients with coronary artery disease experiences angina that is not amenable to revascularization and is refractory to medical therapy. Preclinical studies have indicated that human CD34+ stem cells induce neovascularization in ischemic myocardium, which enhances perfusion and function. METHODS AND RESULTS: Twenty-four patients (19 men and 5 women aged 48 to 84 years) with Canadian Cardiovascular Society class 3 or 4 angina who were undergoing optimal medical treatment and who were not candidates for mechanical revascularization were enrolled in a double-blind, randomized (3:1), placebo-controlled dose-escalating study. Patients received granulocyte colony-stimulating factor 5 microg x kg(-1) x d(-1) for 5 days with leukapheresis on the fifth day. Selection of CD34+ cells was performed with a Food and Drug Administration-approved device. Electromechanical mapping was performed to identify ischemic but viable regions of myocardium for injection of cells (versus saline). The total dose of cells was distributed in 10 intramyocardial, transendocardial injections. Patients were required to have an implantable cardioverter-defibrillator or to temporarily wear a LifeVest wearable defibrillator. No incidence was observed of myocardial infarction induced by mobilization or intramyocardial injection. The intramyocardial injection of cells or saline did not result in cardiac enzyme elevation, perforation, or pericardial effusion. No incidence of ventricular tachycardia or ventricular fibrillation occurred during the administration of granulocyte colony-stimulating factor or intramyocardial injections. One patient with a history of sudden cardiac death/ventricular tachycardia/ventricular fibrillation had catheter-induced ventricular tachycardia during mapping that required cardioversion. Serious adverse events were evenly distributed. Efficacy parameters including angina frequency, nitroglycerine usage, exercise time, and Canadian Cardiovascular Society class showed trends that favored CD34+ cell-treated patients versus control subjects given placebo. CONCLUSIONS: A randomized trial of intramyocardial injection of autologous CD34+ cells in patients with intractable angina was completed that provides evidence for feasibility, safety, and bioactivity. A larger phase IIb study is currently under way to further evaluate this therapy.


Subject(s)
Angina Pectoris/surgery , Peripheral Blood Stem Cell Transplantation , Aged , Aged, 80 and over , Angina Pectoris/chemically induced , Angina Pectoris/diagnostic imaging , Angina Pectoris/drug therapy , Cardiovascular Agents/therapeutic use , Cell Count , Combined Modality Therapy , Double-Blind Method , Electric Countershock , Electrocardiography, Ambulatory , Exercise Tolerance , Female , Granulocyte Colony-Stimulating Factor/adverse effects , Granulocyte Colony-Stimulating Factor/pharmacology , Humans , Injections , Male , Middle Aged , Myocardium , Peripheral Blood Stem Cell Transplantation/methods , Quality of Life , Tomography, Emission-Computed, Single-Photon , Treatment Outcome
4.
J Clin Invest ; 115(2): 326-38, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15690083

ABSTRACT

We have identified a subpopulation of stem cells within adult human BM, isolated at the single-cell level, that self-renew without loss of multipotency for more than 140 population doublings and exhibit the capacity for differentiation into cells of all 3 germ layers. Based on surface marker expression, these clonally expanded human BM-derived multipotent stem cells (hBMSCs) do not appear to belong to any previously described BM-derived stem cell population. Intramyocardial transplantation of hBMSCs after myocardial infarction resulted in robust engraftment of transplanted cells, which exhibited colocalization with markers of cardiomyocyte (CMC), EC, and smooth muscle cell (SMC) identity, consistent with differentiation of hBMSCs into multiple lineages in vivo. Furthermore, upregulation of paracrine factors including angiogenic cytokines and antiapoptotic factors, and proliferation of host ECs and CMCs, were observed in the hBMSC-transplanted hearts. Coculture of hBMSCs with CMCs, ECs, or SMCs revealed that phenotypic changes of hBMSCs result from both differentiation and fusion. Collectively, the favorable effect of hBMSC transplantation after myocardial infarction appears to be due to augmentation of proliferation and preservation of host myocardial tissues as well as differentiation of hBMSCs for tissue regeneration and repair. To our knowledge, this is the first demonstration that a specific population of multipotent human BM-derived stem cells can induce both therapeutic neovascularization and endogenous and exogenous cardiomyogenesis.


Subject(s)
Bone Marrow Cells/physiology , Cell Differentiation/physiology , Heart/physiology , Multipotent Stem Cells/transplantation , Myocardial Infarction/therapy , Regeneration/physiology , Adult , Animals , Bone Marrow Cells/cytology , Cell Lineage/physiology , Cell Proliferation , Cells, Cultured , Female , Humans , Male , Multipotent Stem Cells/physiology , Myocardial Infarction/pathology , Myocardium/pathology , Myocytes, Cardiac/pathology , Myocytes, Cardiac/physiology , Myocytes, Smooth Muscle/pathology , Myocytes, Smooth Muscle/physiology , Neovascularization, Physiologic/physiology , Rats , Rats, Nude
5.
Nat Clin Pract Cardiovasc Med ; 3 Suppl 1: S123-8, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16501618

ABSTRACT

Previous studies have shown that local angiogenic gene therapy acts, in part, by recruiting endothelial progenitor cells (EPCs) to ischemic tissue. Recent data indicate that patients with the most severe vascular disease may have insufficient or deficient EPCs and the poorest response to angiogenic therapy. Accordingly, we hypothesized that combining human CD34(+) cell implantation with local vascular endothelial growth factor 2 (phVEGF2) gene therapy might overcome these deficiencies. The addition of VEGF2 to EPC cultures resulted in significant and dose-dependent decreases in EPC apoptosis. Phosphorylated Akt (p-Akt) was increased in VEGF2-treated EPCs. In vivo, myocardial infarction (MI) was induced by ligation of the left anterior descending coronary artery in 34 immunodeficient rats. The animals were then randomized to one of four treatment groups: cell therapy alone with human CD34(+) cells; VEGF2 gene therapy alone; combination therapy with CD34(+) cells plus phVEGF2; or CD34(-) cells and 50 microg empty plasmid. Four weeks after MI, animals treated with combination therapy showed improved fractional shortening, increased capillary density, and reduced infarct size compared with the other three groups. Combination therapy was also associated with an increased number of circulating EPCs 1 week after MI. Combined subtherapeutic doses of cell and gene therapy result in a significant therapeutic effect compared to monotherapy. This approach may overcome therapeutic failures (e.g. inability of certain patients to mobilize sufficient EPCs) and may also offer safety advantages by allowing lower dosing strategies.


Subject(s)
Antigens, CD34/analysis , Endothelial Cells/transplantation , Myocardial Infarction/therapy , Vascular Endothelial Growth Factors/metabolism , Animals , Apoptosis , Cells, Cultured , Combined Modality Therapy , Disease Models, Animal , Dose-Response Relationship, Drug , Endothelial Cells/drug effects , Endothelial Cells/immunology , Female , Genetic Therapy , Myocardial Infarction/metabolism , Myocardial Infarction/pathology , Myocardium/pathology , Rats , Rats, Nude , Transplantation, Autologous , Vascular Endothelial Growth Factors/genetics , Vascular Endothelial Growth Factors/pharmacology
6.
J Clin Apher ; 21(2): 116-20, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16342193

ABSTRACT

Information on the safety of mobilization and collection of peripheral blood progenitor cells (PBPC) in patients with advanced coronary heart disease (CHD) is limited. We report herein our early experience with patients participating in a Phase I trial of injection of autologous CD 34(+) cells into threatened, ischemic myocardium for neovascularization and symptom relief in patients with chronic refractory myocardial ischemia. All patients had advanced inoperable CHD despite the best medical therapy. Granulocyte colony stimulating factor (G-CSF, 5 microg/kg/day) was administered subcutaneously for 5 days for mobilization of CD34(+) cells into the peripheral blood. PBPCs were collected in the outpatient apheresis suite on day 5. Nine patients from our institution were evaluable. Adverse effects of mobilization included: increase in frequency and/or intensity of angina in 8 patients (88.8%); bone pain in 7 patients (77.7%); headaches in 4 patients (44.4%); 2 patients (22%) were hospitalized. Collection phase toxicities included: tingling in 5 patients (55.5%) and angina in 3 patients (33%). All procedures were completed without new myocardial infarction, congestive heart failure, or death. The median peripheral blood CD34(+) cell count on day 5 of G-CSF was 21 cells/microl (range 10-40 cells/microl). A median of 1.65 x 10(6) CD34(+) cells/kg (range: 0.13-3.0 x 10(6)/kg) were harvested. We conclude that mobilization and collection of PBPC in patients with advanced CHD can be safely performed as an outpatient procedure. Apheresis professionals should be aware of the intensity and frequency of angina in this patient population.


Subject(s)
Coronary Disease/therapy , Hematopoietic Stem Cell Mobilization/adverse effects , Peripheral Blood Stem Cell Transplantation/methods , Aged , Aged, 80 and over , Angina Pectoris/etiology , Chronic Disease , Coronary Disease/complications , Female , Granulocyte Colony-Stimulating Factor/administration & dosage , Headache/etiology , Hematopoietic Stem Cell Mobilization/standards , Humans , Male , Middle Aged , Myocardial Ischemia/therapy , Neovascularization, Physiologic , Pain/etiology , Peripheral Blood Stem Cell Transplantation/adverse effects , Salvage Therapy/methods , Single-Blind Method , Transplantation, Autologous
7.
Proc Natl Acad Sci U S A ; 103(29): 11015-20, 2006 Jul 18.
Article in English | MEDLINE | ID: mdl-16835303

ABSTRACT

The transcription factor E2F1 is known to regulate cell proliferation and has been thought to modulate tumorigenesis via this mechanism alone. Here we show that mice deficient in E2F1 exhibit enhanced angiogenesis. The proangiogenic phenotype in E2F1 deficiency is the result of overproduction of vascular endothelial growth factor (VEGF) and is prevented by VEGF blockade. Under hypoxic conditions, E2F1 down-regulates the expression of VEGF promoter activity by associating with p53 and specifically down-regulating expression of VEGF but not other hypoxia-inducible genes, suggesting a promoter structure context-dependent regulation mechanism. We found that the minimum VEGF promoter mediating transcriptional repression by E2F1 features an E2F1- binding site with four Sp-1 sites in close proximity. These data disclose an unexpected function of endogenous E2F1: regulation of angiogenic activity via p53-dependent transcriptional control of VEGF expression.


Subject(s)
Cell Cycle , E2F1 Transcription Factor/metabolism , Transcription, Genetic/genetics , Tumor Suppressor Protein p53/metabolism , Vascular Endothelial Growth Factor A/biosynthesis , Vascular Endothelial Growth Factor A/genetics , Animals , Cells, Cultured , Down-Regulation , E2F1 Transcription Factor/deficiency , E2F1 Transcription Factor/genetics , Hindlimb/blood supply , Hindlimb/metabolism , Humans , Mice , Mice, Inbred C57BL , Mice, Knockout , Tumor Suppressor Protein p53/genetics
SELECTION OF CITATIONS
SEARCH DETAIL